Man Group plc Invests $6.66 Million in ANI Pharmaceuticals, Inc. $ANIP

Man Group plc purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 80,496 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,663,000.

Several other institutional investors have also made changes to their positions in ANIP. KBC Group NV acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at $28,000. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals in the first quarter worth $28,000. Hantz Financial Services Inc. increased its position in ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after buying an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in ANI Pharmaceuticals during the fourth quarter worth $48,000. Finally, State of Wyoming bought a new position in ANI Pharmaceuticals during the second quarter valued at about $50,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ANIP shares. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Canaccord Genuity Group reduced their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Guggenheim lowered their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $105.83.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 2,850 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.36, for a total transaction of $231,876.00. Following the sale, the chief financial officer owned 174,693 shares in the company, valued at approximately $14,213,022.48. This represents a 1.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $74.30, for a total transaction of $401,220.00. Following the sale, the chief executive officer directly owned 344,489 shares in the company, valued at approximately $25,595,532.70. This represents a 1.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 24,387 shares of company stock worth $1,947,625 over the last 90 days. Company insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $72.83 on Friday. The business has a fifty day simple moving average of $79.68 and a 200 day simple moving average of $78.65. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of 15.70 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a one year low of $70.15 and a one year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same quarter in the prior year, the business posted $1.80 earnings per share. The company’s quarterly revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.